C4 Therapeutics, Inc. (CCCC) company profile

This clinical-stage biopharmaceutical company focuses on developing targeted protein degradation therapies to address unmet medical needs. Utilizing its proprietary TORPEDO platform, the company creates orally bioavailable small-molecule medicines designed to destroy disease-causing proteins via natural cellular processes. Its clinical pipeline features cemsidomide, a molecular glue degrader being evaluated for multiple myeloma, and CFT8919, an allosteric degrader targeting non-small cell lung cancer with specific genetic mutations. The company also advances early-stage discovery programs directed at inflammation, neuroinflammation, and neurodegenerative conditions, serving patient populations facing severe oncologic and neurological disorders.

The company conducts clinical trials and research activities across multiple territories, with clinical development of CFT8919 underway in Greater China through a partnership, while maintaining development rights for other global regions. Additionally, it engages in collaborative research and licensing alliances with major pharmaceutical partners, including Merck KGaA and Roche. The provided text does not state the location of the company's headquarters.

Summary of the business section of C4 Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price is $19.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had 104 full-time employees, including 40 employees with an M.D.”